MoonLake Immunotherapeutics, (MLTX) News

MoonLake Immunotherapeutics, (MLTX): $52.17

0.29 (+0.56%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

D

Add MLTX to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#319 of 334

in industry

Filter MLTX News Items

MLTX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest MLTX News From Around the Web

Below are the latest news stories about MOONLAKE IMMUNOTHERAPEUTICS that investors may wish to consider to help them evaluate MLTX as an investment opportunity.

MoonLake Immunotherapeutics (MLTX) Posts Q3 2023 Results: Clinical Progress Amid Controlled Expenses

MLTX Advances in Clinical Trials with Strong Cash Position

Yahoo | November 14, 2023

MoonLake Immunotherapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update

MoonLake Immunotherapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update Announced positive full 24-week data from the global Phase 2 MIRA clinical trial, establishing the Nanobody® sonelokimab as a highly promising and differentiated therapeutic solution for hidradenitis suppurativa Presented positive 12-week data from the global Phase 2 MIRA clinical trial for sonelokimab in hidradenitis suppurativa at a late-breaking session during the European Academy of Dermat

Yahoo | November 14, 2023

Why Former Highflier MoonLake Plummeted 29% After A Recent Run

MoonLake Immunotherapeutics reported mixed test results for its psoriatic arthritis treatment on Monday, and top-rated MLTX stock crashed.

Yahoo | November 6, 2023

MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis

MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis First placebo-controlled randomized trial in active psoriatic arthritis (PsA) using a Nanobody® to report positive topline results in support of potential best-in-class profilePrimary endpoint ACR50 met with up to 47% (p<0.01 versus placebo) of patients on sonelokimab achieving ACR50 as early as week 12All key secondary endpoints met including up to 77% (p<0.001 versus placebo)

Yahoo | November 5, 2023

12 Best Performing NASDAQ Stocks in 2023

In this piece, we will take a look at the 12 best performing NASDAQ stocks in 2023. If you want to skip our introduction to the NASDAQ’s performance this year and the broader stock market, then read 5 Best Performing NASDAQ Stocks in 2023. The NASDAQ has been one of the best performing stock indexes […]

Yahoo | October 26, 2023

12 Best Performing Biotech Stocks in 2023

In this piece, we will take a look at the 12 best performing biotechnology stocks in 2023. If you want to skip our introduction to the biotechnology industry and some top players, then check out 5 Best Performing Biotech Stocks in 2023. Biotechnology is one of the hottest industries these days and one that has […]

Yahoo | October 20, 2023

MoonLake Immunotherapeutics' Lead Skin Disorder Candidate Continues to Deliver on Best-Efficacy Profile: Analyst

MoonLake Immunotherapeutics (NASDAQ: MLTX) announced 24-week topline results from its Phase 2 MIRA trial of sonelokimab for moderate-to-severe hidradenitis suppurativa (HS), following the 12-week results, in which the primary endpoint was met with 29 percentage points delta versus placebo at week 12. The data showed that the maintenance treatment with its Nanobody sonelokimab led to further improvements in HiSCR75 response rates and other clinically relevant outcomes. The 24-week results show th

Yahoo | October 16, 2023

Why Top-Notch MoonLake Surged 11% And Almost Broke Out

MoonLake beat Wall Street's expectations in an update for its skin-disease treatment. MLTX stock surged near a buy point.

Yahoo | October 16, 2023

MoonLake Immunotherapeutics announces the full dataset from its 24-week MIRA clinical trial, establishing the Nanobody® sonelokimab as a highly promising and differentiated therapeutic solution for Hidradenitis Suppurativa

MoonLake Immunotherapeutics announces the full dataset from its 24-week MIRA clinical trial, establishing the Nanobody® sonelokimab as a highly promising and differentiated therapeutic solution for Hidradenitis Suppurativa (HS) Maintenance treatment with sonelokimab dosed every 4 weeks (Q4W), demonstrated that 57% of patients achieved HiSCR75 at week 24, increasing the landmark week 12 responses (primary endpoint) by over 10 ppt (percentage points)The depth of responses continued to increase fro

Yahoo | October 15, 2023

MoonLake Immunotherapeutics presents positive 12-week data from the Phase 2 MIRA trial with Nanobody® Sonelokimab for Hidradenitis Suppurativa at the European Academy of Dermatology and Venereology Congress

MoonLake Immunotherapeutics presents positive 12-week data from the Phase 2 MIRA trial with Nanobody® Sonelokimab for Hidradenitis Suppurativa at the European Academy of Dermatology and Venereology Congress Peer reviewed data presented during a late-breaking session at the European Academy of Dermatology and Venereology Congress (EADV) confirms the strong profile of sonelokimab in HS announced at MLTX’s R&D Day on June 26, 2023HiSCR75 primary endpoint met with a significantly higher proportion o

Yahoo | October 11, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!